Tonix Pharmaceuticals Secures $34 Million DoD Contract to Develop Broad-Spectrum Antiviral
Tonix gets $34M from DoD to develop broad-spectrum antiviral targeting CD45 protein over five years.
Breaking News
Jul 25, 2024
Mrudula Kulkarni

Tonix Pharmaceuticals has received a significant boost from
the U.S. Department of Defense (DoD) to develop a broad-spectrum antiviral
drug. The company will receive up to $34 million over five years to research
and develop a drug capable of combating a wide range of viruses, including
potential biological threats.
The growing concern over biological warfare and the
increasing prevalence of novel and dangerous viruses drives the need for such a
drug. The DoD aims to protect its personnel from these threats and has
identified antiviral drugs as a critical component of its defense strategy.
Tonix's approach focuses on targeting the CD45 protein,
which plays a role in viral replication. By inhibiting this protein, the
company believes it can create a drug effective against multiple viruses. The
company's state-of-the-art research facilities will be crucial in developing
this drug and advancing it through clinical trials.
This partnership between Tonix and the DoD highlights the
increasing importance of antiviral research and development in the face of
evolving biological threats.